HPV vaccines: Translating immunogenicity into efficacy

被引：22
作者：
Turner, Taylor B. [1 ]
Huh, Warner K. [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Obstet & Gynecol, Div Gynecol Oncol, Birmingham, AL 35294 USA
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2016年 / 12卷 / 06期
关键词：
Human papilloma virus vaccine; immune correlate; VIRUS-LIKE PARTICLES; HPV-16/18 AS04-ADJUVANTED VACCINE; FOLLOW-UP; SUSTAINED EFFICACY; CERVICAL-CANCER; PAPILLOMAVIRUS; ANTIBODIES; INFECTION; PROTECTION; POSTVACCINATION;
D O I：
10.1080/21645515.2015.1103936
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Currently available human papillomavirus (HPV) vaccines are very successful at preventing persistent HPV infection and premalignant cervical lesions. In part due to the unique aspects of HPV immunogenicity and high levels of efficacy no immune correlate has been identified for HPV vaccination. Serum neutralizing antibodies are used to measure vaccine response, but their role as a correlate has not been verified, and this theory fails to explain the prevention of HPV related non-mucosal lesions. Identifying a true correlate would aid in future work in this area but will be difficult in the setting of a highly efficacious vaccine.
引用
收藏
页码：1403 / 1405
页数：3
相关论文
共 23 条
  • [1] Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine
    Belshe, RB
    Gruber, WC
    Mendelman, PM
    Mehta, HB
    Mahmood, K
    Reisinger, K
    Treanor, J
    Zangwill, Z
    Hayden, FG
    Bernstein, DI
    Kotloff, K
    King, J
    Piedra, PA
    Block, SL
    Yan, LH
    Wolff, M
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) : 1133 - 1137
  • [2] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION
    BREITBURD, F
    KIRNBAUER, R
    HUBBERT, NL
    NONNENMACHER, B
    TRINDINHDESMARQUET, C
    ORTH, G
    SCHILLER, JT
    LOWY, DR
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (06) : 3959 - 3963
  • [3] Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection
    Carter, JJ
    Koutsky, LA
    Hughes, JP
    Lee, SK
    Kuypers, J
    Kiviat, N
    Galloway, DA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) : 1911 - 1919
  • [4] MEASLES ANTIBODY - REEVALUATION OF PROTECTIVE TITERS
    CHEN, RT
    MARKOWITZ, LE
    ALBRECHT, P
    STEWART, JA
    MOFENSON, LM
    PREBLUD, SR
    ORENSTEIN, WA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05) : 1036 - 1042
  • [5] FAIRLEY CK, 1994, NEPHROL DIAL TRANSPL, V9, P416
  • [6] Prevention of cervical cancer through papillomavirus vaccination
    Frazer, IH
    [J]. NATURE REVIEWS IMMUNOLOGY, 2004, 4 (01) : 46 - 54
  • [7] Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus
    Ghim, S
    Newsome, J
    Bell, J
    Sundberg, JP
    Schlegel, R
    Jenson, AB
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2000, 68 (03) : 147 - 151
  • [8] Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles
    Ho, GYF
    Studentsov, Y
    Hall, CB
    Bierman, R
    Beardsley, L
    Lempa, M
    Burk, RD
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (06) : 737 - 742
  • [9] ANTIBODIES AGAINST THE HUMAN PAPILLOMAVIRUS TYPE-16 EARLY PROTEINS IN HUMAN-SERA - CORRELATION OF ANTI-E7 REACTIVITY WITH CERVICAL-CANCER
    JOCHMUSKUDIELKA, I
    SCHNEIDER, A
    BRAUN, R
    KIMMIG, R
    KOLDOVSKY, U
    SCHNEWEIS, KE
    SEEDORF, K
    GISSMANN, L
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (22) : 1698 - 1704
  • [10] Leigh I M, 1995, Recent Results Cancer Res, V139, P69
123